Quick verdict: AEHR vs CEVA in 2026

Overall, CEVA holds a notable edge over AEHR based on several key financial metrics and analyst sentiment as of 2026-05-08. CEVA demonstrates stronger momentum in revenue growth, boasts superior profitability margins, and is favored significantly by a larger pool of analysts. While both companies are currently unprofitable, CEVA presents a more compelling profile for growth and relatively better valuation, leading in 8 of 12 comparable metrics in our detailed scorecard. For investors weighing an aehr vs ceva stock comparison 2026, CEVA appears to offer a more stable and analyst-supported investment case. Not investment advice.

AEHR vs CEVA: key metrics side by side

Full side-by-side comparison of AEHR and CEVA across valuation, profitability, growth and analyst sentiment. Data updated 2026-05-08.

AEHR vs CEVA valuation comparison

When evaluating AEHR vs CEVA valuation, both companies present significant challenges for traditional investors given their current unprofitability, as clearly indicated by their negative P/E ratios. AEHR trades at an extraordinarily high P/E of -245.38x, which is drastically steeper in absolute terms compared to CEVA’s P/E of -81.01x. This extreme difference implies that the market is valuing AEHR at a much higher multiple of its negative earnings, suggesting elevated speculative interest or expectations for a significant future turnaround, despite current losses. From a price-to-book (P/B) perspective, CEVA appears considerably more attractive and grounded with a P/B ratio of 2.56x, whereas AEHR’s P/B stands at a notably high 20.18x. This wide discrepancy highlights that AEHR is valued far more richly relative to its tangible book equity, possibly reflecting intangible assets or future growth potential priced in.

Further complicating the aehr vs ceva fundamentals and valuation picture are the discounted cash flow (DCF) analyses, which indicate substantial theoretical overvaluation for both stocks. AEHR shows a DCF upside of -101.7%, implying its current share price is more than double what its projected future cash flows might realistically support. Similarly, CEVA’s DCF upside is an almost identical -102.1%, presenting an equally deep degree of theoretical overvaluation according to this fundamental model. While both stocks are deeply in negative territory by the DCF metric, the less severe negative P/E and significantly lower P/B ratio position CEVA as the comparatively “cheaper” option in this aehr vs ceva valuation comparison. However, investors should note that both are considered heavily overvalued by DCF, suggesting high inherent risk.

AEHR vs CEVA growth comparison

In terms of growth, there is a distinct and impactful divergence between AEHR and CEVA that warrants careful consideration for any aehr vs ceva stock comparison 2026. AEHR has unfortunately experienced a revenue growth of -10.9% year-over-year. This significant contraction in its top-line performance is a critical red flag, signaling potential difficulties in securing new business, maintaining existing contracts, or facing intensified competition within its market. A negative growth trend can erode investor confidence and suggests underlying challenges that are currently hindering the company’s ability to expand its revenue base and market share.

Conversely, CEVA, Inc. demonstrates a modest but positive revenue growth of 2.5% year-over-year. While not indicative of explosive growth, this positive figure signifies that CEVA is managing to grow its sales and expand its operations, albeit at a gradual pace, even in potentially challenging economic environments. This modest, yet positive, growth, coupled with CEVA’s substantially higher absolute revenue figure of $109,598,000 compared to AEHR’s $58,968,000, suggests that CEVA possesses a larger operational scale and is maintaining stronger momentum in its business trajectory. Therefore, for investors prioritizing top-line expansion and market traction in their aehr vs ceva analysis, CEVA clearly exhibits the stronger momentum and a more stable growth narrative.

AEHR vs CEVA profitability

The profitability comparison between AEHR and CEVA reveals that both companies are currently operating at a loss, which is a significant factor in any aehr vs ceva fundamentals and valuation assessment. However, CEVA exhibits a notably less severe degree of unprofitability. AEHR reported a concerning net margin of -25.23%, alongside an even deeper EBITDA margin of -29.97%. These starkly negative figures indicate substantial operational inefficiencies, high fixed costs, or aggressive investments that are currently weighing heavily on the company’s ability to cover its expenses and generate any positive earnings from its revenue streams.

CEVA, while also unprofitable, presents a comparatively more favorable picture with a net margin of -9.71% and an EBITDA margin of -4.12%. These figures, while still negative, suggest that CEVA’s operations are considerably closer to breaking even and demonstrate better cost control compared to AEHR. Neither company provided a return on equity (ROE) figure, which is often the case with unprofitable companies where the metric can be misleading or undefined due to negative equity. Regarding free cash flow (FCF) yield, both are negative, with AEHR at -0.4% and CEVA at -0.67%. Although both indicate that they are consuming cash, AEHR’s FCF yield is marginally less negative, suggesting it’s burning cash at a slightly slower rate relative to its market capitalization. Despite this nuance in FCF, CEVA’s significantly better net and EBITDA margins indicate superior operational efficiency and a more viable path towards potential profitability, making it the less unprofitable option in this AEHR vs CEVA profitability analysis.

Analyst ratings: AEHR vs CEVA

The analyst community presents a stark contrast in their outlook for AEHR vs CEVA, which is a crucial element for anyone considering should I buy aehr or ceva stock 2026. AEHR is covered by a relatively small contingent of just 3 analysts, with only 33.3% recommending a “Buy” rating. The prevailing consensus among these limited analysts is “Hold,” reflecting a cautious or neutral stance on the stock’s immediate future. Furthermore, their average price target of $62 implies a substantial downside of -32.1% from its current price of $91.26. This combination of limited coverage, a predominantly cautious sentiment, and a negative implied price target collectively signals a lack of strong conviction or enthusiasm in AEHR’s near-term prospects from professional research desks.

In sharp contrast, CEVA enjoys much broader coverage from a robust panel of 24 analysts, with an overwhelming 87.5% issuing a confident “Buy” rating. The strong consensus is unequivocally “Buy,” reflecting a high degree of confidence and optimism in the company’s future performance and strategic direction. The average price target for CEVA is $32.5, which, while marginally below its current price of $33.72, represents a much smaller implied downside of -3.6%. The substantially higher number of analysts covering CEVA and their overwhelmingly positive recommendations clearly indicate a strong preference for CEVA over AEHR within the professional investment community, positioning CEVA as the definitive analyst favorite in this critical aehr vs ceva comparison.

Should I buy AEHR or CEVA stock in 2026?

For growth investors in 2026, when considering should I buy AEHR or CEVA stock, CEVA appears to be the more compelling choice. While its revenue growth of 2.5% is modest, it stands in stark contrast to AEHR’s significant revenue contraction of -10.9%. This positive, albeit slow, growth, combined with CEVA’s larger overall revenue base, suggests better market traction and a more stable trajectory for future expansion. Growth-oriented investors typically seek companies demonstrating increasing sales and expanding market share, characteristics that are currently more evident in CEVA’s performance and fundamental outlook compared to AEHR.

From a value investment perspective, especially when scrutinizing aehr vs ceva fundamentals and valuation, CEVA also presents a relatively more appealing profile. Both companies are currently unprofitable, which complicates a straightforward value assessment, but CEVA’s P/E ratio of -81.01x is considerably less negative than AEHR’s -245.38x. More significantly for value metrics, CEVA’s Price-to-Book (P/B) ratio of 2.56x is substantially lower than AEHR’s elevated 20.18x, suggesting that CEVA is valued more reasonably relative to its underlying assets. Although both firms show deeply negative DCF upsides, CEVA’s valuation metrics generally point to a comparatively less expensive entry point for value-conscious investors willing to navigate the complexities of unprofitable technology companies.

For income investors, the decision regarding should I buy AEHR or CEVA stock in 2026 is unambiguous: neither company currently offers a dividend. Both AEHR and CEVA have a dividend yield of 0%, indicating they are either reinvesting all available capital (or covering ongoing losses) back into the business rather than distributing profits to shareholders. Therefore, if generating regular income from stock holdings is a primary investment objective, neither AEHR nor CEVA would be suitable candidates for a dividend-focused portfolio. This analysis is for informational purposes only and is not investment advice; always conduct your own thorough research.

More AEHR and CEVA comparisons

AEHR full stock analysis · CEVA full stock analysis · All stock comparisons

FAQ: AEHR vs CEVA